Viewing Study NCT00493155



Ignite Creation Date: 2024-05-05 @ 5:36 PM
Last Modification Date: 2024-10-26 @ 9:34 AM
Study NCT ID: NCT00493155
Status: COMPLETED
Last Update Posted: 2016-11-02
First Post: 2007-06-27

Brief Title: A Multiple Ascending Dose Study of R1530 in Patients With Advanced Solid Tumors
Sponsor: Hoffmann-La Roche
Organization: Hoffmann-La Roche

Study Overview

Official Title: An Open-label Multiple Ascending Dose Study to Determine the Maximum Tolerated Dose of R1530 in Patients With Advanced Solid Tumors
Status: COMPLETED
Status Verified Date: 2016-11
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This study will determine the maximum tolerated dose and assess the safety tolerability and pharmacokinetics of R1530 administered orally to patients with advanced or metastatic solid tumors R1530 will be administered daily for 14 days at the starting dose this dose will be escalated in subsequent cohorts of patients after a satisfactory assessment of safety and tolerability of the previous dose until the maximum tolerated dose is reached The anticipated time on study treatment is until disease progression and the target sample size is 100 individuals
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None